AICAR: The Exercise Mimetic That Needs Grams, Not Milligrams

At a Glance

AICAR is the original exercise mimetic, and it has an evidence base unlike anything else in this part of the library: not a handful of mouse studies, but a 4,043-patient meta-analysis, a 3,080-patient randomised trial and a formal oncology dose-escalation study. Thousands of people have received it intravenously under trial conditions. We know a great deal about what it does in humans.

What we know is not what the marketing says. The honest verdict comes in three parts. The famous mouse finding is real — AMPK activation improved endurance capacity in untrained animals, which is where “exercise in a pill” came from [3]. The human pharmacodynamics are real but modest: an infusion raised muscle glucose uptake about half as much as actually riding a bicycle did in the same study [1]. And the doses required are measured in grams delivered by continuous infusion, which makes the milligram subcutaneous protocols sold online pharmacologically irrelevant rather than merely unproven.

That last point is what makes AICAR worth a careful page. For most grey-market compounds the criticism is an absence of evidence. For AICAR there is evidence, and it argues against the way the compound is actually being used.

A note on classification: AICAR is a nucleoside, not a peptide. It appears here because it is sold and stacked alongside peptides, and because it is the compound people ask about most often after reading that AMPK activation mimics exercise.

How it works

AICAR enters cells through adenosine transporters and is phosphorylated by adenosine kinase to ZMP (AICAR monophosphate), which structurally mimics AMP. AMPK senses cellular energy status by binding AMP, so ZMP accumulation fools the enzyme into behaving as though the cell is energy-depleted — the state exercise and fasting produce genuinely.

Activated AMPK then does what it does in any context:

• Increases glucose uptake into skeletal muscle via GLUT4 translocation
• Increases fatty acid oxidation, partly by phosphorylating and inhibiting acetyl-CoA carboxylase
• Suppresses ATP-consuming anabolic pathways including lipogenesis and protein synthesis
• Promotes mitochondrial biogenesis over time

This is the same node metformin, berberine and the mitochondrial peptide MOTS-c converge on by different routes, which is why those compounds keep appearing in the same conversations. The MOTS-c article describes an interesting twist: MOTS-c appears to activate AMPK partly by causing endogenous AICAR to accumulate through inhibition of the folate cycle. AICAR is, in that sense, a natural intermediate as well as a drug.

AICAR also has adenosine-regulating activity independent of AMPK, raising local adenosine in ischaemic tissue. That, rather than the metabolic effect, is why it was developed for cardiac surgery.

Three pharmacological facts determine everything practical about this compound: oral bioavailability is poor, the half-life is short, and the intracellular ZMP concentrations needed to activate AMPK are high. Hence infusions, and hence grams.

What the evidence shows

Animal: the famous result

Narkar and colleagues (Cell 2008) tested pathway-specific drugs on treadmill endurance in mice and reported that AMPK and PPARδ agonists act as exercise mimetics, with AICAR improving running performance in sedentary animals and PPARδ agonism showing synergy in trained animals [3]. This paper launched both the exercise-mimetic concept and AICAR’s career as a doping agent.

The gap between that result and human physiology is the theme of everything below.

Human: pharmacodynamics

Muscle glucose uptake. Cuthbertson and colleagues (Diabetes 2007) studied 29 healthy men (mean age 26, BMI 25). Using a primed continuous 2-deoxyglucose infusion to measure muscle glucose uptake, they found that after 3 hours uptake increased 2.1-fold with AICAR and 4.7-fold with bicycle exercise [1]. AICAR does something measurable in human muscle — and exercise does more than twice as much.

Hepatic glucose output and lipolysis. Boon and colleagues (Diabetologia 2008) infused AICAR intravenously in patients with type 2 diabetes. Glucose rate of appearance fell, blood glucose disposal rose as a proportion of appearance, and plasma glucose declined more than in the control test. Plasma non-esterified fatty acid rates of both appearance and disappearance fell significantly, with a decline in NEFA concentration — AICAR inhibited whole-body lipolysis. Notably, AMPK phosphorylation in skeletal muscle was not increased, although acetyl-CoA carboxylase phosphorylation was [2].

That second finding deserves emphasis, because it inverts the fat-loss rationale. A compound marketed for fat burning reduced the release of fatty acids from adipose tissue in the one human study that measured it.

Human: cardiac surgery, where the large trials are

The positive meta-analysis. Mangano (JAMA 1997) pooled individual patient data from five randomised, placebo-controlled, double-blind trials across 81 international centres: 4,043 patients undergoing CABG surgery, randomised to placebo (n = 2,031) or acadesine 0.1 mg/kg/min by intravenous infusion for 7 continuous hours plus drug in the cardioplegia solution (n = 2,012) [6]. A 2006 follow-up analysis reported a long-term survival improvement with adenosine regulation in post-reperfusion myocardial infarction [8].

The definitive negative trial. RED-CABG (Newman, JAMA 2012) was designed to confirm it. A prespecified futility analysis indicated a very low likelihood of a statistically significant efficacious outcome, and the trial was stopped after 3,080 of a planned 7,500 patients had been randomised. The primary outcome occurred in 75 of 1,493 (5.0%) on placebo and 76 of 1,493 (5.1%) on acadesine — odds ratio 1.01, 95% CI 0.73–1.41 — with no differences in key secondary endpoints [7].

Clinical development stopped there. This is the cleanest illustration in the library of why a promising meta-analysis of smaller trials is not the same as a large, well-powered confirmatory trial.

Human: oncology dose-escalation

Van Den Neste and colleagues (Cancer Chemother Pharmacol 2013) ran a multicentre phase I/II study of acadesine in relapsed or refractory chronic lymphocytic leukaemia. Single doses from 50 to 210 mg/kg were given; 210 mg/kg was both the maximum tolerated dose and the optimal biological dose. The safety profile was described as manageable and predictable. Grade ≥2 hyperuricaemia occurred commonly but was managed with prophylactic allopurinol; other adverse events included transient anaemia and thrombocytopenia, renal impairment, and transient infusion-related hypotension described as clinically significant. Trends toward efficacy — reduction of peripheral CLL cells and of lymphadenopathy — were observed but variable given the small population and range of doses [4]. Preclinical work has since reported that acadesine circumvents azacitidine resistance in myelodysplastic syndrome and AML [5].

This study provides the best human dose-response information available for AICAR, and it establishes the scale: the biologically optimal single dose is around 210 mg/kg.

What no human evidence exists for

No human trial of AICAR for endurance performance, weight loss, fat mass, body composition or insulin sensitivity as a therapeutic endpoint. No study of subcutaneous administration. No study at any dose remotely resembling what is sold.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Do the arithmetic, because it settles the question. The cardiac infusion delivers about 42 mg/kg over seven hours, roughly 3 g in a 70 kg adult, intravenously and continuously. The oncology optimal biological dose is 210 mg/kg, around 15 g. A 50 mg subcutaneous injection is about 0.7 mg/kg — somewhere between one-sixtieth and one-three-hundredth of the doses that produced measurable effects in humans, by a slower route, for a molecule with poor bioavailability and a short half-life that needs high intracellular ZMP accumulation to engage its target.

This is not a conservative-versus-aggressive dosing debate. It is a question of whether the compound can engage its target at all at the doses being sold, and the pharmacology says no. The honest conclusion is the one most useful to a reader: AICAR at grey-market doses is an expensive way to inject a nucleoside.

Why nobody simply uses more. Three reasons. Cost — at gram quantities AICAR is prohibitively expensive, which is itself why vendor protocols are in milligrams. Route — oral bioavailability is poor and every human study used continuous intravenous infusion. And safety — at pharmacologically meaningful doses the oncology study documents hyperuricaemia, haematological effects, renal impairment and significant infusion-related hypotension, none of which belong in an unmonitored setting.

Stacks commonly described. AICAR with GW501516 (cardarine, a PPARδ agonist) is the combination taken directly from the Narkar paper [3], and it pairs an underdosed compound with one carrying its own serious preclinical carcinogenicity signal. AICAR with metformin or berberine stacks two AMPK-directed agents, one of which has decades of human outcome data — see metformin vs berberine. Injection technique in general: peptide injection guide.

What people report: what works and what doesn’t

Sources: the human trials above; the 2026 critical review of peptide and peptide-analogue use in sport [9]; and the open community record on r/Peptides and endurance and bodybuilding forums. Community material shows patterns, not proof; no individual account is treated as evidence.

Reported to work

• Very little, consistently. Among the compounds in this library AICAR has an unusually negative anecdotal record, and the pharmacology above explains why.
• Some users describe improved work capacity during training blocks, typically alongside structured training — the classic confound.

Mixed or unclear

• Whether anything is detectable at all at vendor doses. The commonest theme in community discussion is people concluding, after a cycle, that they cannot tell whether they took anything.
• Reports of effects from “high-dose” protocols in the hundreds of milligrams. Still one to two orders of magnitude below trial exposures, and prohibitively expensive to sustain, so they are not informative.
• Whether product sold as AICAR is AICAR. It is a simple, cheap nucleoside to synthesise, which cuts both ways: easy to make correctly and easy to substitute with something cheaper.

Reported not to work / disappointing

• Fat loss. The dominant disappointment, and the one with a mechanistic explanation: the only human study to measure it found AICAR inhibited whole-body lipolysis [2].
• Endurance gains resembling the mouse data. Nobody reports anything like them, and no human trial has looked.
• Cost-effectiveness — repeatedly described as the worst in this category per unit of perceived effect.
• Anti-doping consequences. AICAR is named explicitly on the WADA list and is detectable in urine, with analytical methods developed specifically because of its doping use [9]. Athletes who treated it as obscure have been wrong.

What a properly designed human trial would need to show: an administration route and dose producing sustained AMPK activation in human skeletal muscle — measured directly, since the one study that looked found phosphorylated ACC without increased muscle AMPK phosphorylation [2] — and then, over 8–12 weeks against placebo, improved VO₂max, fat mass or insulin sensitivity. The pharmacokinetics make that a hard trial to design, which is why it has not been run.

Safety and side effects

AICAR has more human safety data than nearly anything else in this library, which makes the specifics worth stating.

At pharmacologically active doses (50–210 mg/kg IV, oncology study) [4]:

• Grade ≥2 hyperuricaemia, common, requiring prophylactic allopurinol. AICAR is a purine analogue, and purine loading raises urate.
• Transient anaemia and thrombocytopenia, described as not clinically significant in that population.
• Renal impairment.
• Transient infusion-related hypotension, described as clinically significant — consistent with the adenosine-regulating mechanism, since adenosine is a vasodilator.

At the cardiac surgery dose (0.1 mg/kg/min for 7 hours), across more than 7,000 patients between the pooled trials and RED-CABG, the drug was tolerated well enough for repeated large trials to proceed [6, 7]. Tolerability was never why development stopped — lack of efficacy was.

Theoretical and unstudied risks relevant to self-administration. Urate elevation matters to anyone with gout or stone disease. AMPK activation blunts some anabolic signalling, which sits awkwardly with hypertrophy goals and parallels the exercise-blunting question raised for metformin — see metformin and exercise. Chronic AMPK activation has preclinical links to effects on cardiac glycogen and on cancer cell metabolism in both directions. None of this has been studied with subcutaneous dosing, because nobody has studied subcutaneous dosing.

Interactions. Adenosine-mediated effects could compound with dipyridamole, adenosine itself or other vasodilators; caution with agents affecting urate; additive AMPK activation with metformin is theoretically plausible and clinically uncharacterised.

Sourcing. Research-chemical supply with unverified identity, purity and sterility — see peptide sourcing.

Legal and regulatory status

United States. Not an approved medicine. Acadesine reached late-stage development for CABG surgery and was not approved; after RED-CABG was stopped for futility in 2012 the programme ended. AICAR does not appear in FDA 503A category 1, so no compounding enforcement-discretion pathway applies — see the FDA 2026 compounding update.

European Union and Germany. No EMA marketing authorisation; sold only as a research chemical.

Sport — where AICAR is a special case. AMPK activators including AICAR are named explicitly in WADA’s section S4 (hormone and metabolic modulators), prohibited at all times, in and out of competition. Validated urinary detection methods exist precisely because of its use in endurance sport, and because AICAR occurs endogenously, testing uses concentration thresholds rather than simple presence. The review literature treats it as an established doping agent rather than a borderline one [9]. See peptides and WADA rules.

How it fits: AMPK activation, five ways

The instructive thing about that table is that the compound with the most human exposure is also the one with the clearest negative result on a hard endpoint, and the one whose actual use pattern is furthest from its studied one. If you want AMPK activation with human outcome data behind it, metformin is a prescription drug with decades of evidence. If you want AMPK activation from exercise, the Cuthbertson study quantified the comparison at the pathway level: riding a bicycle raised muscle glucose uptake more than twice as much as the drug [1].

AICAR remains genuinely important as a laboratory tool — much of what we know about AMPK was established with it — and as the mechanistic bridge that explains part of how MOTS-c works. As a product to inject at 50 mg a day, it is the compound in this library where the published human pharmacology most directly contradicts the marketing.

Related Articles

• MOTS-c Peptide: The Mitochondrial Signal That Reshapes Metabolism — the mitochondrial peptide that works partly by raising endogenous AICAR.
• Metformin vs Berberine — AMPK activation with actual human outcome data.
• Metformin and Exercise: Does It Blunt Training Adaptations? — the question that applies to every AMPK activator used by athletes.
• 5-Amino-1MQ: The NNMT Inhibitor With No Human Data — the other oral metabolic compound sold in this category.
• Peptide Therapy for Athletes: What’s Banned Under WADA Rules — AICAR is one of the few named explicitly.
• Peptide Sourcing: Pharmaceutical-Grade vs Grey Market — what “research use only” means in practice.